Compare Moderna, Inc. (MRNA) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Micron Technology, Inc. — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Micron Technology, Inc. trades at $978.09 (market cap $977.44B). The key difference: Micron Technology, Inc. is far larger — about 41.4× Moderna, Inc.'s market cap, and Micron Technology, Inc. pays a 0.06% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | MU | |
|---|---|---|
Market Cap | $23.60B | $977.44B |
Sector | Health | Technology |
52-Week High | $81.80 | $1.21K |
52-Week Low | $22.36 | $104.88 |
Enterprise Value | $19.70B | $957.80B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Micron Technology (MU) surged 14.36% to $970.82, driven by strong AI memory demand and positive analyst sentiment. The stock shows robust fundamentals with a P/E of 19.56 and net income margin of 55.91%, supported by three consecutive quarterly earnings beats. Technical indicators are mixed, with a bearish moving average signal but oversold RSI levels suggesting potential rebound. Recent news highlights AI-driven memory chip demand and strategic customer agreements fueling growth optimism.
Outlook remains bullish due to AI super-cycle tailwinds and projected 2026 revenue of $90.3B, though risks include cyclical semiconductor demand and high valuation multiples. Analyst consensus strongly favors Buy with a $1,550 price target, indicating ~60% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
